Alex Zhavoronkov
@elonverse.bsky.social
My only objective function is to extend productive longevity for everyone on the planet. Here to share research papers. https://x.com/biogerontology
Endometriosis is not only a huge unmet medical need where advances in AIDD can help hundreds of millions of women over time but it is also a platform for understanding the many biological processes (including cancer and aging) and therapeutic approaches. This problem must be solved in our lifetime
January 17, 2025 at 9:48 PM
Endometriosis is not only a huge unmet medical need where advances in AIDD can help hundreds of millions of women over time but it is also a platform for understanding the many biological processes (including cancer and aging) and therapeutic approaches. This problem must be solved in our lifetime
CUHK is one of the top universities in OBGYN as it gave us non-invasive prenatal diagnostics and testing (NIPD/NIPT) and is the home to *hopefully* the future Nobel laureate, Dennis Lo. This school has advanced experimental models and spectacular clinical base.
January 17, 2025 at 9:48 PM
CUHK is one of the top universities in OBGYN as it gave us non-invasive prenatal diagnostics and testing (NIPD/NIPT) and is the home to *hopefully* the future Nobel laureate, Dennis Lo. This school has advanced experimental models and spectacular clinical base.
The team used Insilico Medicine PandaOmics platform with extensive experimental validation.
IMHO, PRMT5+MAT2A could work even better. Share the paper with your PRMT5-enabled friends.
link.springer.com/article/10.1...
IMHO, PRMT5+MAT2A could work even better. Share the paper with your PRMT5-enabled friends.
link.springer.com/article/10.1...
PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands - Journal of Experimental & Clinical Cancer Research
Background Adenoid cystic carcinoma (ACC) is a rare glandular malignancy, commonly originating in salivary glands of the head and neck. Given its protracted growth, ACC is usually diagnosed in advance...
link.springer.com
January 17, 2025 at 4:01 AM
The team used Insilico Medicine PandaOmics platform with extensive experimental validation.
IMHO, PRMT5+MAT2A could work even better. Share the paper with your PRMT5-enabled friends.
link.springer.com/article/10.1...
IMHO, PRMT5+MAT2A could work even better. Share the paper with your PRMT5-enabled friends.
link.springer.com/article/10.1...
Great to be here! 🙏
December 15, 2024 at 2:57 PM
Great to be here! 🙏
Hello, @aspuru.bsky.social , hola from BlueSky!
December 15, 2024 at 1:51 PM
Hello, @aspuru.bsky.social , hola from BlueSky!
4/ This is a game-changer for 40% of IBD patients who lack effective treatments. Combining AI with biology accelerates therapeutic breakthroughs. 🌟
Full study: [Nature Biotech DOI link]
#IBD #AIinMedicine #DrugDiscovery
Full study: [Nature Biotech DOI link]
#IBD #AIinMedicine #DrugDiscovery
December 15, 2024 at 5:31 AM
4/ This is a game-changer for 40% of IBD patients who lack effective treatments. Combining AI with biology accelerates therapeutic breakthroughs. 🌟
Full study: [Nature Biotech DOI link]
#IBD #AIinMedicine #DrugDiscovery
Full study: [Nature Biotech DOI link]
#IBD #AIinMedicine #DrugDiscovery
3/ Key outcomes: ✅ ISM012-042 is more effective than SOC treatments (e.g., mesalamine) in murine colitis models. ✅ No systemic side effects due to gut-restricted PK. ✅ Phase 1 trials underway (NCT06012578), making strides toward patient-ready IBD therapies. 💊
December 15, 2024 at 5:31 AM
3/ Key outcomes: ✅ ISM012-042 is more effective than SOC treatments (e.g., mesalamine) in murine colitis models. ✅ No systemic side effects due to gut-restricted PK. ✅ Phase 1 trials underway (NCT06012578), making strides toward patient-ready IBD therapies. 💊
2/ ISM012-042 leverages AI-driven drug design (Chemistry42 platform) to overcome limitations of systemic PHD inhibitors, ensuring colon-targeted action while minimizing off-target effects. Preclinical results show:
Enhanced mucosal healing 🛡️
Reduced inflammation 🔥
Restored gut barrier 🧬
Enhanced mucosal healing 🛡️
Reduced inflammation 🔥
Restored gut barrier 🧬
December 15, 2024 at 5:31 AM
2/ ISM012-042 leverages AI-driven drug design (Chemistry42 platform) to overcome limitations of systemic PHD inhibitors, ensuring colon-targeted action while minimizing off-target effects. Preclinical results show:
Enhanced mucosal healing 🛡️
Reduced inflammation 🔥
Restored gut barrier 🧬
Enhanced mucosal healing 🛡️
Reduced inflammation 🔥
Restored gut barrier 🧬